Global Drug Revenue

Part
01
of seven
Part
01

Global Drug Revenue (Row 2 - 6)

The global yearly revenue for acetaminophen, albuterol aerosol, alendronate sodium, and alprazolam as reported in 2017 is:

Acetaminophen: $280M
Albuterol aerosol: $121M
Alendronate sodium: $241M
Alprazolam: $52M

After extensively researching brand and parent company websites, pharmaletters, medical research websites, and pharmaceutical websites, we determined that the global revenue of atenolol is not publicly available. Data regarding the drug's annual revenue in the United States (its largest market), however, is available. The yearly annual U.S. revenue of atenolol as reported in 2017 was $70M.

All information regarding these 5 drugs is provided in rows 2-6 of the attached spreadsheet.

RELEVANT FINDINGS

The trade name of alendronate sodium is Fosamax. Revenue data is most often reported under the trade name.

The trade name of alprazolam is Xanax. Revenue data is most often reported under the trade name.

The trade name of acetaminophen is paracetamol. Revenue data is most often reported under the trade name.


Part
02
of seven
Part
02

Global Drug Revenue (Row 7 - 11)

Due to the fact that generic drugs are sold by many manufacturers under different brand names, there is little data available on their total annual revenues, especially recent ones. However, we were able to calculate, using the estimated CAGR for the years between 2004 and 2014, that in 2017 Azithromycin generated $1,191,317,616 in sales, Cephalexin generated $227,765,538, Cetirizine generated $268,549,156.6, Ciprofloxacin HCl generated $851,821,287.2, and Clonazepam generated $751,721,832.16 in annual revenue. All the information was entered in rows 7 - 11 of the spreadsheet.

METHODOLOGY

In order to answer your question, we first searched for pre-compiled data relating to the total global annual sales revenues for either 2016 or 2017 of Azithromycin, Cephalexin, Cetirizine, Ciprofloxacin HCl and Clonazepam. After a thorough search through academic papers, market reports, online articles and news articles, we found no publicly available data for the years of 2016 and 2017. The main reason for that is possibly because the dates required are very recent, and most data used in recent articles is for previous years, suggesting that recent data is yet to be collected and analyzed. In addition, these are generic drugs that are sold by numerous manufacturers under many brand names, which makes the process of collecting the information difficult as many of the manufacturers are private entities that do not publish their production and financial data.

As such, we triangulated the figures by analyzing trends from years prior to 2016/2017. We were able to locate the average market price for each drug from GoodRx and the amount of consumed drugs for 2004 to 2014 from ClinCalc. Using those numbers, we estimated the CAGR, using a CAGR calculator, for each generic drug and calculated the amount of drugs consumed in 2017. That number was then multiplied bu the average cost per prescription, provided by GoodRx, to get the annual revenue for each drug.

FINDINGS

- Azithromycin

On average, Azithromycin costs $36 per prescription. Given that there were 31,988,786 prescriptions for the drug in 2014 and that the CAGR for the years between 2004 and 2014 was 1.71%, we can calculate that in 2017 the number of prescriptions was 33,092,156. Using that, we can estimate that the total revenue for the drug was $1,191,317,616 (33,092,156 x $36).

- Cephalexin

The average cost of a Cephalexin prescription is currently estimated to be $30.03. In 2014, there were 7,886,065 prescriptions for Cephalexin, an the number of prescriptions has been growing at a CAGR of -1.93% between 2004 and 2014. Using those figures, we can calculate that in 2017 the number of prescriptions would be 7,584,600, which gives a total revenue for the drug of $227,765,538 (7,584,600 x $30.03).

- Cetirizine

A Cetirizine prescription is $23.79 on average. Given that in 2014 there were 12,369,433 prescriptions for Cetirizine and that the CAGR for the years between 2004 and 2014 was -4.47%, we can calculate that in 2017 the number of prescriptions was 11,288,321. Using that, we can estimate that the total revenue for the drug was $268,549,156.6 (11,288,321 x $23.79).

- Ciprofloxacin HCl

We were able to find a report available for the Ciprofloxacin HCL market. However data cannot be accessed unless the report is purchased. We have included it here for convenience.

Fortunately, we do know that Ciprofloxacin's prescriptions cost an average of $40.54. As there were 9,312,320 prescriptions for Ciprofloxacin in 2014 and the CAGR for the years between 2004 and 2014 was 13.94%, we can calculate that in 2017 the number of prescriptions was 12,089,555. Using that, we can estimate that the total revenue for the drug was $490,110,559.7 (12,089,555 x $40.54).

- Clonazepam

The average cost of a Clonazepam prescription is $35.68. Given that in 2014 there were 21,068,437 prescriptions for Clonazepam and that the CAGR for the years between 2004 and 2014 was 6.45%, we can calculate that in 2017 the number of prescriptions was 23,873,915. Using that, we can estimate that the total revenue for the drug was $851,821,287.2 (23,873,915 x $35.68).

CONCLUSION

To sum up, while data is not publicly available for the total revenue generated from Azithromycin, Cephalexin, Cetirizine, Ciprofloxacin HCl and Clonazepam, we were able to use the most recent data available for 2014 and the CAGR for each drug between 2004 and 2015 to calculate revenue estimations for 2017. All the information was entered in the provided spreadsheet.
Part
03
of seven
Part
03

Global Drug Revenue (Row 12 - 16)

While there is no pre-existing public information to fully answer your question, we've used the available data to pull together key findings: The requested information is available in proprietary reports for a price, but we have done our best to provide reasonable triangulations from the available public sources for Fexofenadine, Fluoxetine, and Gabapentin, which has been entered into the project spreadsheet. There was insufficient information to attempt to triangulate Fenofibrate or Furosemide.
Below you'll find an outline of our research methodology to better understand why information you've requested is publicly unavailable, as well as a deep dive into our findings.

METHODOLOGY

We conducted a thorough search for market reports with abstracts and academic papers. In most cases, we located an appropriate market report, but the abstract did not publicize the global sales. (We will show several examples below.) We then broadened our search to other pharmaceutical industry sources and, as a last resort, to trusted media sources in the hopes of finding sufficient information to at least triangulate the global revenue for each drug in question. The results of these searches varied and will be explained in detail for each drug below.
Note that in some cases (most notably Fluoxidine), we were unable to find sources which would enable us to triangulate an answer which had both been written within the last 24 months and had been released to the public domain. We therefore used older sources where available in conjunction with the most recent information available to arrive at a reasonable estimate.

FENOFIBRATE

Fenofibrate was originally branded under the name TriCor, but has since seen its patent expire. The available market reports deliberately do not publicize either the global or North American revenues for this medication. We also reviewed the annual reports for Abbvie, the company which originally patented TriCor. We found that it is rarely even mentioned in more recent reports, and may no longer be a major source of revenue for Abbvie. While we found that the global market for cholesterol-lowering drugs like Fenofibrate is $12 billion, we were unable to locate a source in the public domain for Fenofibrate's share.

FEXOFENADINE

Fexofenadine was originally marketed under the Allegra brand, reaching sales of $1.87 billion in 2004. However, Allegra's sales fell to $445.6 million by 2016 due to the spread of generics. We were unable to find a recent public source for global Fexodenadine sales. Since the drop-off in Allegra is due to the spread of generics, we will for the purposes of triangulation assume that the current global Fexofenadine market is equal to that of Allegra at its height. This is obviously a very rough estimation at best, but we cannot do more with the available public information.

FLUOXETINE

Fluoxetine was originally marketed as Prozac, which is part of the $15 billion global antidepressant market. As in the other cases here, we are unable to locate a public source for the world Fluoxitine market, and so must triangulate an answer: global antidepressant sales in 2005 were $16.5 billion, a little more than the $15 billion reported for 2016. In other words, the market has remained essentially flat for the last decade, and even dropped somewhat. According to a 2014 paper, Eli Lilly's sales for Prozac in 2004 (when their patent ended) equaled $2 billion. We therefore estimate that global Fluoxidine sales today equal about $1.8 billion (15 / 16.5 * 2 billion).

FUROSEMIDE ORAL

While we were able to locate two market reports on the global Furosemide market, neither provided global sales in their abstracts. A chart in the second report indicates that at least 85% of Furosemide sales in 2017 were for oral intake, whether in a tablet or solution. Furosemide is a diuretic taken to treat hypertension, so we attempted to determine the size of that market in the hopes of triangulating an answer, but the available market reports for the Global Anti-Hypertensive Drugs Market likewise lacked a total revenue in their abstracts. Unfortunately, without any data to use to establish a baseline, we are unable to estimate the size of Furosemide's market.

GABAPENTIN

As in several of the previous drugs, Gabapentin has its own market reports, but these reports do no publicize the total global revenue. Interestingly, one report details that there were 64 million Gabapentin prescriptions in the US in 2016, but while reporting the sales of Gabapentin's sister drug Pregabalin, it does not give the sales revenue for Gabapentin. The average retail price for Gabapentin is $76.05 for 90 capsules, but the same prescription can be found for as low as $11.65.
The global epilepsy market was $5.4 billion in 2016, with approximately 52% of customers being in the US. This suggests that there were approximately 123 million Gabapentin prescriptions worldwide ((64 million / 52) * 100). Taking the low end of the retail cost of Gabapentin, this gives us a global market of $1.4 billion. Given that Gabapentin is not in the top three best-selling drugs, this seems on the high end. However, Gabapentin is also prescribed for certain types of nerve pain, which in our judgment makes the above estimate more reasonable.

CONCLUSION

In two of the five cases above, Fenfibrate and Furosemide (oral), we were unable to find sufficient public information to triangulate the global revenue. In the other three cases, we have been forced to triangulate the answer based on very little public data. Consequently, if precise figures are required, it may be advisable to purchase one or more of the market reports referenced above. We have nevertheless included our estimations in the project spreadsheet.

Part
04
of seven
Part
04

Global Drug Revenue (Row 17 - 21)

While there is no pre-existing information to fully answer your question, we've used the available data to pull together key findings: Apart from Lansoprazole, whose global sales we were able to pull from the financial reports of the company that produces it, we were unable to locate recent information on the global sales of the requested drugs. For the sake of completing the project spreadsheet, we have used older data and accounted for global population growth and inflation; however, these results must be used with caution, as explained below.
Below you'll find an outline of our research methodology to better understand why the information you've requested is publicly unavailable, as well as a deep dive into our findings.

METHODOLOGY

We conducted a thorough search through market reports and pharmaceutical industry literature in our attempt to find recent sales figures for each of the medications in question. While market reports are most often proprietary and expensive, they often contain at least the value of the market in the abstract. However, this proved not to be the case here; while market reports are available in most cases, the abstracts have been deliberately scrubbed of any useful information. We next attempted to determine global sales figures by studying the financial reports of the manufacturers. With one exception (see below), this also did not produce the requested information. As a final effort, we conducted a broad search of all available public sources; this produced some data, but the available data is five or more years old. Ordinarily, we eschew such data in favor of sources less than 24 months old; however, in this case, the older data is all that is available in the public domain.
We have therefore attempted to triangulate the answer based on the older data and taking inflation and population growth into account. This calculation is based on the assumptions that the increase in a drug's market precisely tracks with inflation and population and is not affected by the spread of generics. Very obviously, these assumptions are grossly oversimplified. Nevertheless, it is the only feasible way to triangulate the requested information from the available public data, even if the results must be taken with a very large grain of salt.

HYDROCHLOROTHIAZIDE

The total worldwide sales of Hydrochlorothiazide in 2012 came to USD $10.1 billion, with $3.4 billion coming from sales in the US. The world population grew 6.2% from 2013 to 2017 (1 - 7.1 billion / 7.6 billion). If the Hydrochlorothiazide market grew at the same pace, it came to $3.6 billion, which, adjusted for inflation comes to $3.84 billion.

HYDROCODONE/APAP

All the various blends of Hydrocodone-APAP sold 37.8 million units in 2013 for a total worldwide market of $1.02 billion. The world population grew 5.3% from 2013 to 2017 (1 - 7.2 billion / 7.6 billion). If the Hydrocodone-APAP market grew at the same pace, it came to $1.07 billion, which, adjusted for inflation comes to $1.12 billion.

IBUPROFEN

Ibuprofen had a global revenue of $1.98 billion in 2011. The world population grew 7.9% from 2011 to 2017 (1 - 7.0 billion / 7.6 billion). If the Ibuprofen market grew at the same pace, it came to $2.14 billion, which, adjusted for inflation comes to $2.33 billion. More precise information about the global Ibuprofen market is available from Reports n’ Reports.

LANSOPRAZOLE

In 2016, Takeda Pharmaceutical reported their global Lansoprazole sales as JPY 89.5 billion, which equals USD $830 million. More precise information about the global Lansoprazole market can be found in a MRS Research Group report.

LEVOFLOXACIN

In 2010, Levaquin (Levofloxacin) sold $1.4 billion worldwide. The world population grew 9.2% from 2010 to 2017 (1 - 6.9 billion / 7.6 billion). If the Levofloxacin market grew at the same pace, it came to $1.53 billion, which, adjusted for inflation comes to $1.72 billion. More precise information about the global Levofloxacin market is available from Allied Market Research.

CONCLUSION

Apart from Lansoprazole, we were unable to locate recent information on the global sales of the requested drugs. We have done our best to triangulate reasonable numbers for the project spreadsheet, but due to the lack of available recent data, these numbers must be taken advisedly. If precision is required, it may be necessary to purchase one or more of the available market reports.
Part
05
of seven
Part
05

Global Drug Revenue (Row 22 - 26)

Generic drugs are sold by many manufacturers under different brand names. This makes it difficult to find the exact revenues earned for the drugs listed under rows 22-26 in the spreadsheet. We were able to find the global market value of Lisinopril in 2017 is estimated to be about $2.25 billion. For Loratadine, we were unable to estimate the figures for 2016/2017. However, we found that in 2013, the global sales of Loratadine was estimated to be about $3.2 billion. We were unable to find or estimate the global revenues for Lorazepam, Losartan Potassium and Metoprolol Tartrate. However, we found other relevant statistics for these drugs which we have provided in the findings below. Please note that the global revenues of all the drugs listed in rows 22-26 are available through paid sources.

METHODOLOGY

We tried to find pre-compiled reports for the global revenues in 2016/2017 for Lisinopril, Loratadine, Lorazepam, Losartan Potassium and Metoprolol Tartrate. We found this information but all the reports were paid ones. Thus, we tried to estimate the figures. But given that all of these drugs are generics and hence can be manufactured by multiple companies across the world, we were unable to do so. The price variations of each of these drugs across different countries and the multiple companies that manufacture these drugs across the world were the main reasons why were unable to estimate the drug revenues globally. However, we found a few figures that can serve as proxies for the global revenues, such as the USA revenues of these drugs, past revenues, and revenues of major companies that manufacture these drugs.

FINDINGS

LISINOPRIL

This drug falls under the ACE inhibitors drug group. The ACE inhibitors market size in 2017 was estimated to be about $11.84 billion as per the report by ProfShare. The market share of Lisinopril globally was estimated to be about 19%. Thus, the Lisinopril market in 2017 globally can be estimated to be about $2.25 billion (19% * $11.84 billion). Additional paid content regarding global revenues for Lisinopril can be obtained here.

LORATADINE

We were unable to find the global market revenue of this drug in 2017/2016. However, in 2013, the global market revenue of Loratadine was about $3.2 billion. Despite searching extensively, we were unable to find any projected growth/de-growth percentage for this drug publicly, we were unable to estimate the revenues for 2017 or 2016 for this drug. Additional paid content regarding global revenues for Loratadine can be obtained here.

LORAZEPAM

To estimate the global revenue for Lorazepam, we tried to first find the Benzodiazepine, which is used to treat anxiety and depression, global market since Lorazepam fall under this category. Using this, we would be able to estimate the market share of Lorazepam amongst other drugs (such as Diazepam, Alprazolam etc) in Benzodiazepine group. However, we were unable to find this information as well. Hence, in the spreadsheet, we have marked the row 24 as N/A. Additional paid content regarding global revenues for Lorazepam can be obtained here.

LOSARTAN POTASSIUM

The global revenue for Losartan Potassium was not available pre-compiled on publicly accessible sources. This drug is mainly sold by Merck under the brand names of Cozaar and Hyzaar. Although there are other companies that manufacture Losartan Potassium, Merck is a leader for this drug. Hence, the sales of Cozaar and Hyzaar will serve as a proxy for the global revenue of this drug. In 2017, the global revenue of Cozaar and Hyzaar, together, stood at $484 million. Additional paid content regarding global revenues for Losatan Potassium can be obtained here.

METOPROLOL TARTRATE

We were unable to estimate the global revenues of this drug since we could not find any previous years' data on its sales. We were also unable to find the sales of Lopressor, the brand name under which Novartis sells this drug. Since this drug falls under the drug group of beta blockers, we tried to find the market size of this group and then the market share of Metoprolol Tartrate within it. However, we were unable to find this information publicly. However, we found that in the USA, in 2016, the Metoprolol Tartrate tablets' revenue across different manufacturers was about $69 million. Additional paid content regarding global revenues for Metoprolol Tartrate can be obtained here.

CONCLUSION

In summary, the global revenue for Lisinopril in 2016 is estimated to be about $2.25 billion. In 2013, the global revenue of Loratadine was $3.2 billion. The sales of Cozaar and Hyzaar in 2017, the brand names under which Merck sells Losartan Potassium and is one of the leaders in the market, was $484 million. The sales of Metoprolol Tartrate in the USA in 2017 was estimated to be $69 million. We were unable to estimate publicly available data about the global market revenues for the rest of the drugs, although we have provided links to paid content that contains this information, when available.
Part
06
of seven
Part
06

Global Drug Revenue (Row 27 - 31)

While there is no preexisting public information to fully answer your question, we've used the available data to pull together key findings:
Global revenue for Nasonex (mometasone furoate monohydrate) in 2017 was $387 million. In 2017, Oxycontin (oxycodone) sales were $1.94 billion. Sales of omeprazole (Prilosec and OTC Prilosec) were over $525 million in 2017. Actos, the brand name for pioglitazone hydrochloride had 2010 sales of $4.3 billion, globally, and $160.8 million in the first half of 2014, but all pioglitazone hydrochloride market reports are paywalled. Darvocet, the brand name for Propoxyphene-N/APAP, was banned by the US, UK, and EU, and therefore, no revenue data was publicly available.

The publicly available data has been provided in the project spreadsheet. Below you'll find an outline of our research methodology to better understand why the information you've requested is publicly unavailable, as well as a deep dive into our findings.

METHODOLOGY

To find the requested data, I have searched for market reports for the drugs identified. However, I found that market reports were either unavailable or paywalled. Therefore, I expanded my search to include pharmaceutical industry sources, such as Fierce Pharma and Pharmacy Times, in search of articles or analyses of the specified drugs. In most cases, my search led to sales data for branded versions of each drug. In the case of pioglitazone hydrochloride, I located numerous market reports, but the data was behind a paywall. Propoxyphene-N/APAP, under the brand name Darvocet, has largely been banned and, therefore, revenue data was not available.

mometasone furoate monohydrate

Mometasone furoate monohydrate, a nasal allergy medication, was sold exclusively under the brand name Nasonex until 2014 and lost its US market exclusivity in 2016. Nasonex revenue for 2017 was $387 million, down from $537 million in 2016. In 2015, it had sales of $858 million.

No market reports were available for generic versions of mometasone furoate monohydrate. I attempted to find data on Nasonex's market share among this drug category with the hope of triangulating the overall category. However, available market reports for the global allergic rhinitis market were paywalled. So we have provided the 2017 global figure for Nasonex in the attached spreadsheet, as a proxy for the overall mometasone furoate monohydrate market.

Omeprazole

Revenue data for omeprazole, a proton pump inhibitor (PPI) sold primarily under the Prilosec brand name, is largely hidden in paywalled market reports for both omeprazole and the larger PPI category. However, 2017 revenue for "prescription Prilosec and OTC Prilosec exceeded $525 million." In 2010, omeprazole (noted primarily as Prilosec) made up about 28.8% of the proton pump inhibitor market. However, since PPI market reports are paywalled, I was unable to use this data to estimate. Therefore, I will use the revenue figure for Prilosec as a proxy in the attached spreadsheet.

OXYCODONE

Market reports for oxycodone are also paywalled. The drug has primarily been marketed under the Oxycontin brand name. Oxycontin, manufactured by Purdue, saw its peak sales in 2013, but sales dropped to $1.94 billion in 2017, about $1 billion less than in 2013. I attempted to find revenue data for other brand names for oxycodone, but that data proved to be unavailable. I also tried to find Oxycontin's market share among the oxycodone drugs, but that information proved elusive. So, I am providing the sales data for Oxycontin as a proxy in the attached spreadsheet.

Pioglitazone Hydrochloride

Several market reports are available for pioglitazone hydrochloride, but they are all paywalled. The drug has primarily been sold under the brand name Actos, but the patent expired in 2012. In 2010, Actos had global sales of $4.3 billion. In the first half of 2014, sales were $160.8 million. I looked for CAGR data that might allow me to triangulate a more recent figure, but again, this information was paywalled. Despite extensive searches through corporate and industry sources, I was unable to find any additional recent data for Actos or the overall pioglitazone hydrochloride market. Therefore, having insufficient data to calculate a reasonable estimate for 2016 or 2017, I have entered N/A in the spreadsheet.

Propoxyphene-N/APAP

Propoxyphene-N/APAP is a combination drug consisting of propoxyphene and acetaminophen. It was primarily sold under the brand name Darvocet. However, this drug was banned by the US in 2010, as well as in the UK in 2005 and the EU in 2009. Therefore, no recent revenue data available. I searched for data on the sales of Propoxyphene-N/APAP in other countries, but I was unable to find this information, despite searching sources such as the World Bank and the World Drug Report from the United Nations Office on Drugs and Crime. Therefore, I have entered N/A on the spreadsheet.

CONCLUSION

In conclusion, the available revenue data for mometasone furoate monohydrate, omeprazole, oxycodone, pioglitazone hydrochloride, and Propoxyphene-N/APAP has been provided in the attached spreadsheet.
Part
07
of seven
Part
07

Global Drug Revenue (Row 32 - 37)

While there is no preexisting information to fully answer your question, I used the available data to pull together key findings: I was able to locate information that allowed me to triangulate estimates for each of the drugs listed in rows 32-37 of the attached spreadsheet, except for Triamterene w/HCTZ and Venlafaxine Hydrochloride, which were publicly unavailable.

I have organized and summarized my results in the attached spreadsheet. Below, you'll find an outline of our research methodology to better understand why information you've requested is publicly unavailable, as well as a deep dive into our findings.

METHODOLOGY

I conducted an exhaustive search of corporate websites, market reports, white papers, trust media sites and pharmacology reports, but unfortunately could not find any revenue information for Triamterene w/HCTZ or Venlafaxine Hydrochloride. I also searched prescription sales, percentage of users and conducted a Google X-ray search, but again was unsuccessful.

FINDINGS/ CALCULATIONS

The global yearly revenue for each of the drugs listed is as follows:

Sertaline-Apprx. $293,038,200

I was able to locate Q3 sales for Zoloft for 2017. According to the Market Realist, Zoloft “generated revenues of $78 million, which is a 13% growth on a quarter-over-quarter basis”. I used a 13% CAGR to calculate Q1 at $59,038,200 and Q2 at 67,860,000. Q4 was not published, therefore I estimated it using a 13% CAGR. ($88,140,000.) This would make the annual revenue approximately $293,038,200. I used a CAGR calculator to perform these calculations.

Simvastin-$186,000,000

I was able to locate the full-Year 2016 Financial Results for Merck & Co, which is the manufacturer of Zocor, the commercial name for Simvastatin, which reports sales at $186,000,000 for 2016.

Tamsulosin Hydrochloride-$2,975,000,000.

In 2017, Flomax held 85% market share of the $3.5 billion dollar market.
$3,500,000,000 x .85 = This would equal a revenue of $2,975,000,000.

Warfarin- Apprx $3,000,000,000

According to the Montley Fool, Warfarin holds 30% of a $10 Billion market. ($10,000,000,000 x .3 = $3,000,000,000)

CONCLUSION

I have organized and summarized my research findings in the attached spreadsheet and have triangulated estimates for drugs located in rows 32-37, as per your request. I hope that you find this useful!


Sources
Sources

From Part 03
From Part 05
From Part 06